Glaxo S.p.a.

Dino Micheli

Giovanni Gaviraghi

Claudio Semeraro

Daniele Pieraccioli

Alan D Borthwick

Allan D Borthwick

Compounds are described of the formula: ##STR1## and physiologically acceptable salts thereof, in which R.sub.1 -R.sub.7 are defined hereinafter. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion concentration and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

Heterocyclic compounds and their preparation and pharmaceutical

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;

Heterocyclic compounds and their pharmaceutical formulation

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group:

Heterocyclic 1,4 dihydropyridine derivatives

1.4-dihydro pyridines

Pyridinedicarboxylic acid derivatives and pharmaceutical compositions

1.4-dihydropyridines

Compounds are described of the formula ##STR1## wherein R.sub.1 represents a formyl or nitrile group or a group OCH.sub.2 A where A represents hydroxy, C.sub.1-4 alkoxy or D(CH.sub.2).sub.n NR.sub.7 R.sub.8 (where R.sub.7 and R.sub.8 independently represent hydrogen or C.sub.1-4 alkyl and n is 2 or 3);

Growing community of inventors

Carpi, Italy

Dino Micheli